Anupam Rasayan: 297% PAT Surge – Agrochemical Alchemy or Just a One-Quarter Wonder?
1. At a Glance
Anupam Rasayan’s Q1 FY26 results are the financial equivalent of a Bollywood blockbuster opening weekend — Revenue up 89%, EBITDA up 118%, PAT up 297%. Order book? A thumping ₹14,646 crore. But before you start writing “chemical multibagger” in your diary, note the P/E is a nosebleed 102× and ROE is still only 3.33%. It’s like owning a Lamborghini that’s currently stuck in second gear.
2. Introduction
Founded in Surat, this specialty chemicals manufacturer has become a darling of the “China+1” supply chain shift. They make high-value life science intermediates for agrochemicals, personal care, and pharmaceuticals, selling both in India and globally.
In theory, Anupam should be a consistent compounding machine — diversified customers, long-term contracts, high entry barriers. In practice, the last few years have been a mixed cocktail of growth spurts, high receivables, and underwhelming returns on equity. Q1 FY26 looks great on paper — but the million-rupee question is: can they repeat it without the chemical equivalent of a miracle monsoon?
3. Business Model (WTF Do They Even Do?)
Business Verticals (FY24 revenue share):
Life Science Specialty Chemicals (91%):
Agrochemicals (65%): Intermediates and active ingredients for insecticides, fungicides, herbicides.
Personal Care (17%): UV filters, antibacterial actives.
Pharma (9%): Intermediates and key starting materials for APIs.
Other Specialty Chemicals (9%): Custom synthesis, high-performance materials.
Revenue comes from long-term contracts with marquee global clients. The idea is to be “sticky” — once a customer’s process uses your chemistry, switching is costly and risky.
